Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Mol Cancer Res. 2016 Sep 13;14(11):1124–1135. doi: 10.1158/1541-7786.MCR-16-0083

Figure 2. DZNep inhibits TGF-β1 synthesis and secretion in pancreatic cancer.

Figure 2

A. DZNep decreased TGF-β1 protein in a time- and dose-dependent manner. Whole cell lysates (50 μg) of DZNep-treated cells subjected to Western blotting for TGF-β1 expression. A rhTGF-β1 used as a positive control and β-actin as a loading control. B. DZNep decreased TGF-β1 protein in PDAC cell lines. C. DZNep mediated decrease in TGF-β1 was independent of transcriptional changes. Densitometric values of TGF-β1 protein (A, right) and transcript levels were compared. GUSB used as an internal control for qRT-PCR. D. DZNep reduced TGF-β1 secretion into the culture supernatants. The extent of decrease in secretion was measured by ELISA. E. DZNep attenuated TGF-β1 signaling in a dose-dependent fashion. Whole cell lysates of PANC-1 treated with TGF-β1 (10 ng/mL; 60 mins) and DZNep (24 h pre-treatment) subjected to Western blotting for total and p-Smad2. F. DZNep decreased transcript levels of TGF-β-responsive genes as determined by qRT-PCR. Points, mean of triplicate; bars, SD. n=3.